Locanabio, Inc. today announced that data from LBIO-115, its vectorized snRNA exon skipping program in development for the treatment of Duchenne muscular dystrophy (DMD) with mutations amenable to exon 51 skipping, and its Cas13d-mediated program for C9orf72-related amyotrophic lateral sclerosis (ALS) will be presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting.
Locanabio to report preclinical data from snRNA exon skipping program in DMD and Cas13d-mediated C9orf72 ALS program
SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with rare genetic neuromuscular and neurodegenerative diseases, today announced that data from LBIO-115, its vectorized snRNA exon skipping program in development for the treatment of Duchenne muscular dystrophy (DMD) with mutations amenable to exon 51 skipping, and its Cas13d-mediated program for C9orf72-related amyotrophic lateral sclerosis (ALS) will be presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting. The ASGCT meeting is being held from May 16-20, 2023, in Los Angeles, CA.
Details of Locanabio’s ASGCT Presentation Abstracts
Title: Small Nuclear RNA-mediated Exon51 Skipping AAV9 Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
Presenting Author: Rea Lardelli Markmiller, Ph.D.
Session Title: Thursday Poster Session
Session Date and Time: Thursday May 18, 2023, Noon – 2:00 pm PT
Abstract Number: 1198
Title: Cas13d Multi-targeting Efficiently Targets Sense and Antisense HRE Containing Toxic RNAs and poly-GP DPR in C9ALS Patient Cells and in C9-BAC500 Mouse Model
Presenting Author: Daniela Martino Roth, Ph.D.
Session Title: Thursday Poster Session
Session Date and Time: Thursday May 18, 2023, Noon – 2:00 pm PT
Abstract Number: 811
All posters will be available for registered attendees for on-demand viewing on the ASGCT website on May 16, 2023, beginning at 6:00 AM ET. Upon release at ASGCT, Locanabio’s presentations will also be available on the scientific resources page of Locanabio’s website.
About Locanabio, Inc.
Locanabio is a leader in developing a new class of genetic medicines that has the potential to significantly improve the lives of patients with devastating genetic diseases by correcting the message of disease-causing RNA. Our proprietary platform uses gene therapy to deliver RNA-binding systems, including snRNA, Cas13d, and PUF that can be engineered to selectively manipulate disease-causing RNA by multiple mechanisms. Our systems are designed to provide a durable therapy with a single administration without altering a cell’s DNA. Locanabio’s platform has applications across a range of tissues and diseases, and we are currently advancing programs in rare genetic neuromuscular and neurodegenerative diseases. For more information, visit www.locanabio.com.
Investor and Media Contacts:
Sylvia Wheeler
Wheelhouse LSA
swheeler@wheelhouselsa.com
Elizabeth Wolffe, Ph.D.
Wheelhouse LSA
lwolffe@wheelhouselsa.com
